Culture

Otago study examines attitudes toward climate change risk

image: Study supervisor, Professor Nancy Longnecker of the University of Otago's Centre for Science Communication

Image: 
University of Otago

A University of Otago study explored factors which influence Americans' levels of concern over climate change, providing discussion on how those factors could impact mitigation efforts.

A key thread of the research examined the ability of people to visualize the future. Results showed that while 74 per cent of respondents were concerned about climate change, only 29 per cent discussed lower carbon options when asked to describe travel in the year 2050.

"This suggests actively envisioning a sustainable future was less prevalent than climate change concern. So while the majority were concerned, there was a disconnect with expectations of what the future might hold," says lead author Jean Fletcher, who completed the study as part of her PhD in Otago's Centre for Science Communication.

The study discusses how mitigation efforts such as greater adoption of low carbon systems could be more widely accepted and happen sooner if expectations of a low carbon future were more prevalent.

"For example, if people expect vehicles will, rather than might, switch from petrol to electric, the uptake of electric car purchasing would likely increase sooner," Miss Fletcher says.

The study also describes how the abstract nature of 'the future' may inspire procrastination as people wait for more information before making a decision.

"This has important implications for climate change. The cumulative nature of carbon emissions means the longer we wait to reduce emissions, the more drastic the emission reduction needs to be," Miss Fletcher adds.

Study supervisor, Professor Nancy Longnecker of Otago's Centre for Science Communication, says that the study's finding of a link between technological optimism and climate change concern suggests that individuals are hoping for technological fixes rather than making personal lifestyle changes. She notes that individual action, collective action and policy are all necessary components in global response to climate change.

"For policy makers, knowing drivers behind people's thinking can help communicate measures to mitigate climate change in ways that lead to action, instead of people either seeing the problem too far away to worry about, too difficult to fix, or being someone else's responsibility," Professor Longnecker says.

Credit: 
University of Otago

Immune system sets 'tripwire' to protect against viruses

image: A new study by UC San Diego biologists has revealed insights on the intricate, adaptive mechanisms of a protective system employed by the cells of mammalian immune systems. These defenses have evolved to set a type of tripwire that produces an immune response against attack from viruses.

Image: 
Brian Tsu, Daugherty Lab, UC San Diego

Scientists are opening new windows into understanding more about the constantly shifting evolutionary arms race between viruses and the hosts they seek to infect. Host organisms and pathogens are in a perennial chess match to exploit each other's weaknesses.

Such research holds tantalizing clues for human health since the immune system is on constant alert to deploy counter measures against new viral attacks. But unleashing too much of a defensive response can lead to self-inflicted tissue damage and disease.

A new study published in the journal eLife by biologists at the University of California San Diego has revealed insights on the intricate, adaptive mechanisms of a protective system employed by the cells of mammalian immune systems. Through a multidisciplinary approach that combined bioinformatics, biochemistry and virology, Biological Sciences graduate students Brian Tsu, Chris Beierschmitt and Andy Ryan, Assistant Professor Matt Daugherty and their collaborators at UC Berkeley found surprising defensive functions coordinated by a protein called NLRP1, which serves as a sensor for invasive pathogens.

The study involved Picornaviridae family viruses, which generate proteases, or molecular "scissors," that can cleave and activate NLRP1. These viruses include human pathogens such as poliovirus, coxsackievirus (responsible for hand, foot and mouth disease) and rhinovirus (one of the most frequent causes of the common cold). The analysis revealed that NLRP1 has recently evolved to "sense" these viral proteases through a type of trap that sets off an immune response in reaction to being cut by the viral proteases. Interestingly, NLRP1 has evolved to do this by mimicking natural sites that the viral protease normally needs to cut in order for the virus to replicate, making it difficult for the virus to avoid cleaving NLRP1 while maintaining its ability to survive.

"In our paper we're showing that NLRP1 acts to bait viral protease cleavage and set off a sort of alarm, or tripwire, in the organism," said Tsu, the lead author of the study. "This is like an Achilles heel to the virus. This allows the host organism to evolve ways to take advantage of this evolutionarily constrained cleavage."

Daugherty said the results offer an interesting switch of conventional beliefs about virus-host dynamics.

"We often think of viruses taking advantage of the fact that hosts evolve slowly, but we're seeing that the hosts have turned the tables and used the fact that the viruses are really stuck here to their advantage, and therefore they use this constraint to activate an immune response."

While evolution is often considered to occur one step after another, the viruses analyzed in this study would need to simultaneously alter numerous regions within their viral proteins to evolve around the tripwire defense, which would be extremely difficult.

The research was derived in cells but lays the groundwork for potential future clinical applications in which the tripwire function could be employed in immune defenses in human systems such as the lungs, brain and other areas. Based on the study's results in individual cells, new research avenues are opening to investigate how the tripwire operates across entire organisms.

"I'm particularly excited about looking for more of these cases because this is an evolutionarily elegant way of detecting and responding to viral infection," said Daugherty.

Credit: 
University of California - San Diego

New biosensors quickly detect coronavirus proteins and antibodies

image: An illustration of a new biosensor binding to a targeted molecule and emitting light. The creation of the biosensor was led by the UW Medicine Institute for Protein Design.

Image: 
Ian Haydon/UW Medicine Institute for Protein Design

Scientists have created a new way to detect the proteins that make up the pandemic coronavirus, as well as antibodies against it. They designed protein-based biosensors that glow when mixed with components of the virus or specific COVID-19 antibodies. This breakthrough could enable faster and more widespread testing in the near future. The research appears in Nature.

To diagnose coronavirus infection today, most medical laboratories rely on a technique called RT-PCR, which amplifies genetic material from the virus so that it can be seen. This technique requires specialized staff and equipment. It also consumes lab supplies that are now in high demand all over the world. Supply-chain shortfalls have slowed COVID-19 test results in the United States and beyond.

In an effort to directly detect coronavirus in patient samples without the need for genetic amplification, a team of researchers led by David Baker, professor of biochemistry and director of the Institute for Protein Design at UW Medicine, used computers to design new biosensors. These protein-based devices recognize specific molecules on the surface of the virus, bind to them, then emit light through a biochemical reaction.

Antibody testing can reveal whether a person has had COVID-19 in the past. It is being used to track the spread of the pandemic, but it ,too, requires complex laboratory supplies and equipment.

The same team of UW researchers also created biosensors that glow when mixed with COVID-19 antibodies. They showed that these sensors do not react to other antibodies that might also be in the blood, including those that target other viruses. This sensitivity is important for avoiding false-positive test results.

"We have shown in the lab that these new sensors can readily detect virus proteins or antibodies in simulated nasal fluid or donated serum, said Baker. "Our next goal is to ensure they can be used reliably in a diagnostic setting. This work illustrates the power of de novo protein design to create molecular devices from scratch with new and useful functions."

Beyond COVID-19, the team also showed that similar biosensors could be designed to detect medically relevant human proteins such as Her2 (a biomarker and therapy target for some forms of breast cancer) and Bcl-2 (which has clinical significance in lymphoma and some other cancers), as well as a bacterial toxin and antibodies that target Hepatitis B virus.

Credit: 
University of Washington School of Medicine/UW Medicine

New study: Which beverages burst with umami potential?

A fifth basic flavour has crept into our conceptualisation of foods in recent years--umami. In Japanese, umami translates roughly to 'savoury deliciousness'.

It is often associated with the earthy flavours of meat, mushrooms, broths and vine-ripened tomatoes. It enhances saltiness and sweetness, while reducing bitterness, which is why most people love it.

But does umami exist in beverages? And if so, which fermented beverage has the most umami potential: wine, beer, sake or champagne? And, what happens to flavours when these beverages are paired with foods?

Three researchers from the University of Copenhagen's Department of Food Science have published this first of a kind study in the journal Food Chemistry.

"We investigated the average umami flavour content in a range of wines, champagnes, beers and sakes. Our analyses demonstrate that it is in sake (Japanese rice wine), where umami reigns supreme on the umami scale, far ahead of beer, followed by champagne and finally wine. However, we studied slightly fewer beers than the other beverages, so that class of beverage may have been difficult to score precisely," reports postdoctoral researcher Charlotte Vinther Schmidt, one of the study's authors.

Higher potential when paired with food

Determining the umami flavour content of a drink involves finding out how much of an amino acid known as glutamic acid there is in it.

Umami flavour reaches us by way of glutamate as it lands on the specialised "umami" taste receptors of our tongues.

"Our results suggest that the longer a beverage's fermentation time, the higher its glutamate content--which leads to more umami flavour. This is probably why sake leads the pack by so much in terms of umami, as it is typically fermented using both yeast and a mold culture called koji," explains Charlotte Vinther Schmidt.

But even if other beverages can't match sake's umami flavor on their own, UCPH's savoury-deliciousness experts assert that the flavour can be provoked by pairing.

"We already know about food combinations which pair happily--like ham and cheese, for example. Therefore, we calculated the effects of pairing shellfish like oysters, shrimp and scallops with the various beverages, so as to investigate which combinations would synergize and provoke an emergence of umami. Here, we conclude that each of the beverage classes studied elicit an umami flavour when paired with oysters and tuna. Furthermore, sake, certain aged wines and champagne can also exhibit umami flavour when paired with scallops," explains CharlotteVinther Schmidt.

According to the researchers, this is because pairing high-content glutamate drinks with foods high in ribonucleotides (RNA's building blocks), catalyzes a synergistic flavour magic through which the best qualities of both drink and food emerge.

"If one takes a drink with glutamate and a food with just as many ribonucleotides, the umami flavour can generally be multiplied by eight," explains Charlotte Vinther Schmidt.

Useful knowledge for sustainable eating

Knowing how to enhance umami is useful when it comes to a more sustainable diet, as Charlotte Vinther Schmidt explains:

"If we can understand which vegetables, that together with selected beverages, provide the best taste--that umami contributes to--we could probably get far more people to consume vegetables, which is healthy for us humans, as well as for our planet."

So, there is good reason to consider the rapport between a meal's food and drink, as Charlotte Vinther Schmidt concludes:

"Although there are other factors contribute to taste experiences, like mouthfeel and smell, it might be a good idea to buy beverages with a high concentration of umami, as they improve the chance of enhancing taste in high-ribonucleotide foods, thus resulting in the delightful savoury-deliciousness of umami."

FACTS:

Average umami flavour content in selected beverages:

The researchers studied 8 sakes, 9 types of white, rosé and sparkling wines, 9 champagnes and 5 types of beer. Here is the average umami content for each beverage class:

Sake = 20,1

Beer = 5,7

Champagne = 4,2

Wines = 3.5

Credit: 
University of Copenhagen - Faculty of Science

Humanizing yeast ORC sheds light on cancer therapy and human development

Researchers from the Hong Kong University of Science and Technology (HKSUST) and the University of Hong Kong (HKU) recently demonstrated that the selectivity determinant of Origin Recognition Complex (ORC) for DNA binding lies in a 19-amino acid insertion helix in the Orc4 subunit, which is present in yeast but absent in human. Removal of this motif from Orc4 transforms the yeast ORC, which selects origins based on base-specific binding at defined locations, into one whose selectivity is dictated by chromatin landscape (genomic nucleosome profile), a characteristic feature shared by human ORC.

Further understanding of the preferred DNA shapes and nucleosome positioning requirements will provide new insights for the plasticity of the human ORC in selecting replication initiation sites during programmed development and disease transformation, and also help identify potential targets for anti-cancer drug screening and therapy design.

All living creatures, from simple unicellular yeast to complex multicellular human being, propagate through cell divisions. Each division requires the exact replication of the genome DNA, which is the blueprint of the identity of every organism. Over-replication may lead to cancers and under-replication may lead to developmental defects such as Meier-Gorlin syndrome. DNA replication is initiated at replication origins by ORC and other protein complexes assembled at these sites.

Interestingly, ORC is highly conserved in protein structure and function from yeast to human, but targets DNA sites that bear no obvious common features in these two systems. What causes this difference? This question had puzzled the scientists for decades.

"Structure informs function," said Prof. Bik TYE, lead researcher and Senior Member of the Institute for Advanced Study, HKUST. "In 2018, we solved a high-resolution structure of the yeast ORC using cryo-electron microscopy. When we compared the structures between yeast and human, we found one important difference between them, which lies in one subunit of ORC--Orc4."

"The yeast Orc4 has an additional 19-amino acid motif which makes specific contacts with origin DNA and is not present in human," said Prof. Tye. "We immediately realized that this short motif of Orc4 might be a critical factor that causes the different behaviors of ORC in DNA binding between yeast and human. We then deleted this motif in yeast cells to test if it could convert the yeast ORC into one that behaves with human-like properties. Indeed, the engineered ORC in yeast behaves more like a human ORC, or as we call it, a humanized ORC."

DNA replication is one of the most fundamental processes in living cells. It is catalyzed by a similar set of replication machineries from yeast to human. In yeast cells, DNA replication starts from a set of sites, termed as replication origins. These sites share a specific DNA sequence, which can be recognized by a six-subunit protein complex known as origin recognition complex (ORC), Orc1-6. ORC binds to origin DNA, then serving as a platform to recruit Mcm2-7 helicase onto DNA. Mcm2-7 helicase is the machine responsible for separating double-stranded DNA to provide templates for DNA replication.

"The activities of each origin are tightly regulated to ensure genome integrity," said Prof. ZHAI Yuanliang, collaborator of the study and Assistant Professor at the School of Biological Sciences, Faculty of Science at HKU. "Mis-regulation of replication initiation can cause either under- or over-replication of chromosomal DNA, which will induce DNA strand breaks, gross chromosomal rearrangements, and genome instability, a characteristic of almost all human cancers."

Inhibition of replication initiation is considered as an effective anti-cancer strategy for the selective killing of cancer cells through apoptosis while normal human cells arrest in G1 state (growth) or withdraw from the cell cycle into G0 state (inactive).

"Our studies lay a solid foundation to identify pairs of interactions, that are critical for origin recognition and helicase loading, with the potential as targets for anticancer drug screening and design," Prof. Zhai noted.

"This study demonstrates the power of multi-disciplinary approaches to answer fundamental questions in life sciences." commented Prof. Danny LEUNG, Assistant Professor at the Division of Life Science, HKUST, and Director of HKUST's Center for Epigenomics Research. Prof. Leung's team was responsible for the epigenomics and bioinformatic analyses of this study. The Center coordinates the efforts of the Hong Kong Epigenomics Project and facilitates regional researchers in carrying out epigenomic studies.

"It began with the atomic model of the yeast ORC bound to origin DNA and the discovery that a single motif in one of the subunits is responsible for the base-specific recognition of DNA by ORC. We conducted genome-wide assays and biochemical experiments to define binding characteristics, which led to the model that removal of this motif is the basis for the behavior of the human ORC, culminating in an insight for the evolution of ORC as eukaryotes adopt more complex genomic and epigenomic structures. This insight also bears critical information on disease transformation that is often associated with the plasticity of DNA replication," Prof. Leung observed.

Credit: 
Hong Kong University of Science and Technology

Scientists discover a new promising target for diabetes treatment

image: Model of insulin inhibitory receptor 'inceptor' (in black) desensetizing the insulin recptor (in color) on a pancreatic beta cell. Insulin in blue.

Image: 
Helmholtz Zentrum München

Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum Muenchen, the Technical University of Munich and the German Center for Diabetes Research is a significant milestone for diabetes research as the scientific community celebrates 100 years of insulin and 50 years of insulin receptor discovery. The blocking of inceptor function leads to an increased sensitisation of the insulin signaling pathway in pancreatic beta cells. This might allow protection and regeneration of beta cells for diabetes remission.

Diabetes mellitus is a complex disease characterized by the loss or dysfunction of insulin-producing beta cells in the islets of Langerhans, a specialist "micro-organ" in the pancreas that controls systemic blood sugar levels. Diabetes complications, such as chronic high blood sugar, systemic metabolic failure and, in the long-term, multi-organ damage, create enormous medical and social burdens and leads to premature death. Currently no pharmacological treatment can stop or reverse disease progression. Previous studies have demonstrated that intensive insulin therapy has the potential for improved blood sugar control and diabetes remission but also leads to unintended weight gain and even more severe side effects, such as an increased risk of deep drop in blood sugar causing unawareness.

Heiko Lickert's* research focuses on the development of regenerative approaches to treat diabetes complementary and alternative to the classical immunological and metabolic therapies. "Insulin resistance in pancreatic beta cells causes diabetes. Therapies that sensitize those cells to insulin may protect patients with diabetes against beta cell loss and failure", says Lickert. With the discovery of the insulin inhibitory receptor, his research group has found a promising molecular target for beta cell protection and regeneration therapy that does not carry the unintended side effects of intensive insulin therapy.

In experiments with mice, the researchers showed that the function of inceptor is to shield the insulin-producing beta cells from constitutive insulin pathway activation. Remarkably, inceptor is upregulated in diabetes and by blocking insulin signaling it might contribute to insulin resistance.

What happens if the function of inceptor is inhibited genetically or pharmacologically? The group explored this question by knocking out inceptor in beta cells and by blocking its function using monoclonal antibodies. "The result was exactly what we were hoping for: Insulin signaling and the functional beta cell mass was increased. This makes inceptor a very promising target to treat the root cause of diabetes, the loss and dysfunction of beta cells," says Ansarullah, one of the first-authors of the study published in Nature and diabetes researcher at Helmholtz Zentrum München.

"Frederick Banting noted already in his Nobel Prize lecture for the discovery of the life-saving drug insulin a hundred years ago that 'Insulin is not a cure for diabetes, but a treatment of the symptoms'. This has not changed in the last century. Our goal for future research is to leverage on the discovery of inceptor and develop drugs for beta cell regeneration. This could be beneficial for patients with type 1 and 2 diabetes and ultimately lead to diabetes remission", states Lickert.

"A hundred years ago, the discovery of insulin has transformed a deadly illness into a manageable disease. Our discovery of the insulin inhibitory receptor now is another important step to finally get rid of the disease," says Matthias Tschöp, CEO at Helmholtz Zentrum München. "While the COVID-19 pandemic represents an immediate threat we will overcome, we must not forget that diabetes remains one of the biggest and fastest growing killers on our planet. With a series of recent breakthroughs, now including the discovery of inceptor, our Helmholtz Diabetes Center is doubling down on its mission that is a world without diabetes."

Credit: 
Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH))

How heavy is dark matter? Scientists radically narrow the potential mass range for the first time

Scientists have calculated the mass range for Dark Matter - and it's tighter than the science world thought.

Their findings - due to be published in Physics Letters B in March - radically narrow the range of potential masses for Dark Matter particles, and help to focus the search for future Dark Matter-hunters. The University of Sussex researchers used the established fact that gravity acts on Dark Matter just as it acts on the visible universe to work out the lower and upper limits of Dark Matter's mass.

The results show that Dark Matter cannot be either 'ultra-light' or 'super-heavy', as some have theorised, unless an as-yet undiscovered force also acts upon it.

The team used the assumption that the only force acting on Dark Matter is gravity, and calculated that Dark Matter particles must have a mass between 10-3 eV and 107 eV. That's a much tighter range than the 10-24 eV - 1019 GeV spectrum which is generally theorised.

What makes the discovery even more significant is that if it turns out that the mass of Dark Matter is outside of the range predicted by the Sussex team, then it will also prove that an additional force - as well as gravity - acts on Dark Matter.

Professor Xavier Calmet from the School of Mathematical and Physical Sciences at the University of Sussex, said:

"This is the first time that anyone has thought to use what we know about quantum gravity as a way to calculate the mass range for Dark Matter. We were surprised when we realised no-one had done it before - as were the fellow scientists reviewing our paper.

"What we've done shows that Dark Matter cannot be either 'ultra-light' or 'super-heavy' as some theorise - unless there is an as-yet unknown additional force acting on it. This piece of research helps physicists in two ways: it focuses the search area for Dark Matter, and it will potentially also help reveal whether or not there is a mysterious unknown additional force in the universe."

Folkert Kuipers, a PhD student working with Professor Calmet, at the University of Sussex, said:

"As a PhD student, it's great to be able to work on research as exciting and impactful as this. Our findings are very good news for experimentalists as it will help them to get closer to discovering the true nature of Dark Matter."

The visible universe - such as ourselves, the planets and stars - accounts for 25 per cent of all mass in the universe. The remaining 75 per cent is comprised of Dark Matter.

It is known that gravity acts on Dark Matter because that's what accounts for the shape of galaxies.

Credit: 
University of Sussex

People with severe atopic eczema may have increased risk of death from several causes

A new study has shown that, while there is limited evidence for overall increased mortality in patients with atopic eczema, those with severe atopic eczema may have a greater risk of dying from several health issues compared with those without eczema, according to a new study in the Journal of Allergy and Clinical Immunology.

The research team, led by the London School of Hygiene & Tropical Medicine (LSHTM) and funded by the Wellcome Trust, compared the risk of dying in over 500,000 adults with atopic eczema with more than 2.5 million without eczema. Patients with severe atopic eczema had a 62% higher risk of dying compared to individuals without atopic eczema, due to several causes - the strongest links of which were seen for infections, lung problems and kidney or bladder disorders.

There was limited evidence of increased 'all-cause' mortality in patients with non-severe atopic eczema, and the absolute risk of death was modest, with low overall mortality rates (1435 per 100,000 people per year in those without atopic eczema, and 1496 per 100,000 people per year in those with atopic eczema).

The researchers did not set out to find the reasons behind the increases in risk of death in severe or predominantly active atopic eczema. Previous studies have suggested that the elevated risk may be linked to reduced physical activity and reduced sleep quality, as well as immunological dysfunction due to the disease itself or the drug treatments the patients might be on. They urge for more research into the causes to help develop intervention strategies.

The research was conducted in collaboration with Health Data Research UK, Aarhus University Hospital, Nottingham Support Group for Carers of Children with Eczema and the University of California San Francisco School of Medicine.

Atopic eczema affects up to 10% of adults and is becoming more common globally. The disease is characterised by itch, sleeplessness and adverse effects on quality of life. Around 30% of people with atopic eczema have moderate to severe disease.

Sinéad Langan, Professor of Clinical Epidemiology at LSHTM, said: "Recent evidence has led to a paradigm shift in how atopic eczema is perceived, from focusing on skin symptoms and associated allergic diseases, to understanding that the disease may be associated with a range of important medical outcomes. Recently, we found atopic eczema to be associated with an increased risk of myocardial infarction, ischemic stroke, angina and heart failure.

"However, few studies have assessed if atopic eczema increases the risk of death, a research question we aimed to address in this study."

This new research used the healthcare records from UK general practices alongside hospitalisation records and mortality data from the Office for National Statistics spanning 1998 to 2016. More than 500,000 people with atopic eczema, of which nearly 35,000 were classified as having severe atopic eczema, were matched with up to five individuals without eczema, based on their age (within 15 years), sex and general practice. This resulted in more than three million individuals were successfully matched, with a median age of 41.8 years.

The researchers found that patients with atopic eczema had 8% to 14% increased risk of death due to infectious, digestive and genitourinary causes.

Crucially, they noted that increased mortality risk was mainly in those with the most severe or more active atopic eczema. Patients with severe atopic eczema had 62% higher overall risk of death. These findings are consistent with previous studies.

Long-standing patient collaborator, Amanda Roberts, said: "Forewarned is fore-armed. Now we eczema patients can be more aware of potential harms and complications associated with lungs, kidneys or bladder. This research team is adding so much to our understanding of eczema."

Professor Langan added: "Although the absolute risk of death from severe eczema is low, our findings suggest that those with severe or more active forms of the disease do face a higher risk of dying from associated health issues. We hope that this new information will help inform further research to better understand this pattern and the underlying mechanisms of these associations, and subsequently inform and improve treatment processes for those with severe eczema."

The researchers acknowledge the limitations of this study, including a lack of standardised measures of disease severity. Severity had to be identified based on hospital referral or receiving of specific therapies, prevent the researchers from disentangling the effects of treatment and severity.

Credit: 
London School of Hygiene & Tropical Medicine

History of the Champagne vineyards revealed

image: Pressing residues from the Place de la Libération site, Troyes (Aube). The plant remains have been preserved in water because they came from the base of a well. Grape seeds, pedicels, skin and leaf fragments can be seen.

Image: 
Véronique ZECH-MATTERNE/AASPE

Although the reputation of Champagne is well established, the history of Champagne wines and vineyards is poorly documented. However, a research team led by scientists from the CNRS and the Université de Montpellier at the Institut des sciences de l'évolution de Montpellier* has just lifted the veil on this history by analysing the archaeological grape seeds from excavations carried out in Troyes and Reims. Dated to between the 1st and 15th centuries AD, the seeds shed light on the evolution of Champagne wine growing, prior to the invention of the famous Champagne, for the first time. According to the researchers, "wild"** vines were cultivated throughout the period studied. Domestic varieties, coming from the south of Gaul, appeared as early as the 1st century and became the major grape varieties of the 2nd and 3rd centuries. This archaeological series was uninterrupted until around 1000 AD, when the wild vine and the southern varieties made a strong comeback. This period corresponds both to intense economic and societal changes and to global warming spanning a few hundred years. Northern grape varieties, more adapted to the cold, appeared more than 300 years later at the beginning of a colder climatic period***, supplanting the southern grape varieties. Published in Scientific Reports on January 27, 2021, these results pave the way for further global analysis that will allow a better understanding of the history of viticulture by combining biological, archaeological and historical data.

Credit: 
CNRS

Well connected through amides

Linking molecular components through amide bonds is one of the most important reactions in research and the chemical industry. In the journal Angewandte Chemie, scientists have now introduced a new type of reaction for making amide bonds. Called an ASHA ligation, this reaction is fast, efficient, works under mild aqueous conditions, and is broadly applicable.

Amide bonds are the bond between a carbonyl carbon (C=O) and an organic nitrogen atom. It is amide bonds that link individual amino acids together into proteins and bind monomers into polyamide plastics like perlon and nylon. Many life-saving medicines such as taxol, lipitor and penicillin, as well as agrochemicals, biological conjugates, natural substances, and other products contain amide bonds. In addition to the classical method of production--the reaction of an acid group (-COOH) with an amino group (-NH(2))--a variety of different reactions have been developed for the formation of amide bonds. However, many of them are not broadly applicable due to a lack of chemoselectivity. They also require specialized coupling agents. New types of reactions are in demand.

A team led by Rajavel Srinivasan at Tianjin University (China) was searching for an efficient, sustainable method that starts with easily accessible materials and works fast. They chose a reaction between acylsilanes and hydroxylamines (a class of organic nitrogen compounds with an -N-O- linkage). Acylsilanes are a class of organic silicon compounds with a general structural formula of R(CO)-SiR(3). Their reactivity often differs completely from that of the related ketones. Although their chemistry is well known, they have previously rarely been used in the field of biomedical chemistry.

Based on their first letters, the reaction of acylsilanes with hydroxylamines is called an ASHA ligation. The driving force appears to be intramolecular migration of a silyl group from a carbon atom to an oxygen atom (Brook rearrangement), in which a strong Si-O bond is formed.

The researchers successfully tested the ligation with a broad palette of different molecular building blocks, including pharmaceutical agents, peptides, natural products, and other biologically active compounds. The reaction is chemoselective and works under mild conditions in an aqueous milieu. It produces high yields in the majority of cases and is tolerant toward most functional groups. New variants of ASHA ligation are in development for peptide synthesis as it did not work well.

However the simplicity and efficiency of the ASHA ligation should open pathways to new approaches in medicinal chemistry and chemical biology, such as fragment-based drug development, in which active substances are built up successively from small fragments.

Credit: 
Wiley

Findings may help close door on COVID-19

image: Jennifer Gribble, a graduate student in the laboratory of Mark Denison, MD, at Vanderbilt University Medical Center.

Image: 
Vanderbilt University Medical Center

Researchers at Vanderbilt University Medical Center (VUMC) and the University of Texas Medical Branch (UTMB) at Galveston have discovered what may be the Achilles' heel of the coronavirus, a finding that may help close the door on COVID-19 and possibly head off future pandemics.

The coronavirus is an RNA virus that has, in its enzymatic toolkit, a "proofreading" exoribonuclease, called nsp14-ExoN, which can correct errors in the RNA sequence that occur during replication, when copies of the virus are generated.

Using cutting-edge technologies and novel bioinformatics approaches, the researchers discovered that this ExoN also regulates the rate of recombination, the ability of the coronavirus to shuffle parts of its genome and even pull in genetic material from other viral strains while it replicates in order to gain evolutionary advantage.

These patterns of recombination, the researchers reported last week in the journal PLOS Pathogens, are conserved across multiple coronaviruses, including SARS-CoV-2, which causes COVID-19, and MERS-CoV, which causes a similar illness, Middle Eastern respiratory syndrome.

"The coronavirus exoribonuclease is therefore a conserved, important target for inhibition and attenuation in the ongoing pandemic of SARS-CoV-2, and in preventing future outbreaks of novel coronaviruses," concluded the paper's first author, Jennifer Gribble, a VUMC graduate student in the laboratory of Mark Denison, MD.

"If you can find a drug that prevents RNA recombination, you really shut down the virus," added Andrew Routh, PhD, assistant professor of Biochemistry and Molecular Biology at UTMB and, with Denison, the paper's co-corresponding author. "It's really intriguing in terms of what we understand about virus adaptation and evolution."

Previous studies have shown that coronaviruses are resistant to many nucleoside antiviral drugs, which work by introducing errors in the viral genetic code to block replication. The coronavirus proofreader corrects the errors so replication can proceed.

Only a few drugs are capable of circumventing the proofreader. They include an approved drug, remdesivir, and EIDD-2801 (molnupiravir), an investigational drug now in clinical trials. Both were developed with the help of VUMC scientists.

"Finding that the viral ExoN plays a key role in recombination is exciting," said Denison, director of the Division of Pediatric Infectious Diseases at VUMC who has studied coronaviruses for more than 30 years.

"Knocking out this function (in laboratory studies) leads to decreased recombination and a weaker virus," Denison said. "So we think it may be possible to block this process with drugs as well (and) that it may make other drugs like remdesivir and molnupiravir work even better and last longer."

In 2007 Denison and his colleagues discovered the coronaviruses proofreader. They also found that blocking the enzyme accelerated the rate of uncorrected errors -- mutations--and crippled its ability to cause disease in animals.

Several years later they discovered that remdesivir, an investigational antiviral drug, had highly potent activity against a wide range of coronaviruses, both in laboratory and animal tests. In October 2020 remdesivir was approved for emergency use in patients hospitalized with COVID-19.

For the past two years, Gribble and Routh have collaborated in an effort to understand the role of recombination in the replication of RNA viruses, which include influenza, polio, measles, hepatitis C, HIV and Ebola, as well as the coronaviruses.

Using computational software Routh had developed, which can scour virus-sequencing datasets for evidence of "recombination events," Gribble was studying recombination in model experimental viruses, such as coronaviruses that infect mice.

Once the pandemic hit, Routh, Gribble and their colleagues were quickly able to apply this approach to SARS-CoV-2 and other coronaviruses that cause disease in humans. Other VUMC co-authors were Laura Stevens, MS, Maria Agostini, PhD, Jordan Anderson-Daniels, PhD, James Chappell, MD, PhD, Xiaotao Lu, MS, and Andrea Pruijssers, PhD.

Recombination does not always result in a "fitter," potentially more virulent virus, Routh noted. If during recombination, for example, some of the genome is deleted, the result is a "defective" viral genome that can mix with, and disable, the more virulent strain.

Coronaviruses frequently produce defective genomes, the researchers found. "That could be useful," Routh said. "You might be able to exploit defective genomes as a way of making new vaccines ... or to perturb replication (of a more virulent strain) ... in the patient."

Much remains to be learned about recombination and the role that plays in the continued spread of evolving variants of SARS-CoV-2 around the world and the ability of anti-viral drugs and vaccines to stop it.

That's why basic science is so important, said Denison, who holds the Edward Claiborne Stahlman Chair in Pediatric Physiology and Cell Metabolism in the Vanderbilt University School of Medicine.

"We need to understand the capacity of all kinds of viruses to move between species and the mechanisms by which they cause disease," he said. "We need to make sure that there are fundamental things that we know about all identified viruses -- their genomic sequences, for example, and some basics about their biology."

That takes a lot of creativity, determination -- and money. Funding for this study was provided by National Institutes of Health grants AI108197, GM065086 and AI133952, the Dolly Parton COVID-19 Research Fund and the Elizabeth B. Lamb Center for Pediatric Research at Vanderbilt.

Credit: 
Vanderbilt University Medical Center

Culture shapes willingness to share personal data to reduce COVID-19 spread

image: Junghwan Kim, a graduate student in geography and geographic information science at the University of Illinois Urbana-Champaign, co-led a study of people's attitudes toward sharing their geographic data with public health officials.

Image: 
Photo by Fred Zwicky

CHAMPAIGN, Ill. -- Culture, civic-mindedness and privacy concerns influence how willing people are to share personal location information to help stem the transmission of COVID-19 in their communities, a new study finds. Such sharing includes giving public health authorities access to their geographic information via data gathered from phone calls, mobile apps, credit card purchases, wristband trackers or other technologies.

Reported in the International Journal of Geo-Information, the study will help public health officials better tailor their COVID-19 mitigation strategies to specific cultural contexts, the researchers said.

The scientists assessed survey responses from 306 people living in the United States and South Korea. Participants were recruited through social media and were younger and more highly educated than the general population of those countries. Conducted in late June and early July, the surveys asked participants to rate their privacy concerns, perceptions of social benefit and acceptance of a variety of COVID-19 mitigation efforts that involve collecting geographic data from individuals.

"For each method, we wanted to see how these factors influenced people's willingness to share their data," said Junghwan Kim, a graduate student in geography and geographic information science at the University of Illinois Urbana-Champaign who led the research with Mei-Po Kwan, a geography professor at The Chinese University of Hong Kong and Kim's doctoral adviser at the U. of I.

Understanding the factors that influence these decisions is key to designing effective public health campaigns, Kim said. What works in one society may not be viable in a different part of the world.

Participants answered questions about conventional contact tracing, where public health officials call those who test positive for the virus to interview them about where they've been and whom they've potentially exposed. Such methods are time-consuming and inefficient, however, so the researchers also asked participants to rate their attitudes toward public health efforts that collect geolocation information from their phones, track their credit card purchases, ask them to wear a wristband or require that they carry a "travel certificate" demonstrating that they have tested negative for COVID-19.

The surveys also asked subjects to rate how they felt about the public disclosure of location, gender and age information of those who tested positive for the virus, or for the sharing of the public locations they had visited without disclosure of their gender and age.

The team found that people were more concerned about - and less likely to accept - methods that collected more sensitive and private information.

"Not surprisingly, we saw that there is a trade-off relationship between privacy concerns and social benefits," Kim said. "So, there is more acceptance when a person's privacy concern is low and the perceived social benefits are high. We also found that people in South Korea have a significantly higher acceptance of most mitigation efforts than those in the U.S."

This higher acceptance may have to do with South Korea's previous experience with the Middle East respiratory syndrome, which is caused by a much deadlier coronavirus than the one that causes COVID-19, Kwan said. But it likely also is a reflection of South Korea's culture.

"Compared with people in the U.S., South Koreans have a stronger collectivist - rather than individualist - culture," she said. "They also have lower privacy concerns and perceive greater social benefits for COVID-19-mitigation measures."

"The results have important public health policy implications," the researchers wrote. For example, the use of phone-based or wristband GPS tracking "would not be effective in the U.S. and other countries where people's acceptance of these methods is very low." Other approaches, such as random phone calls to monitor people's compliance with quarantine orders or the use of travel certificates that verify a person's COVID-19-negative status, would likely work better in such societies.

Credit: 
University of Illinois at Urbana-Champaign, News Bureau

Antibiotic may improve outcomes for depression in people with low level inflammation

King's College London researchers have found evidence that minocycline, a widely used antibiotic with anti-inflammatory properties, gave greater improvement in depressive symptoms in patients with treatment resistant depression with low-grade peripheral inflammation.

Improvement in depressive symptoms
In a four-week randomised clinical MINDEP (MINocycline in DEPression) trial, 39 patients with major depressive disorder were recruited from services linked to South London and Maudsley NHS Foundation Trust (SLaM) and via public advertisement.

The trial took place at the NIHR / Wellcome Trust King's Clinical Research Facility at King's College Hospital. The patients, who were taking their routine antidepressant treatment, were split into two groups, one group took daily a placebo (sugar pill) tablet while the other group took daily minocycline alongside their routine treatment for 4 weeks.
Both groups showed similar, significant improvement in depressive symptoms as measured by the Hamilton Depression (HAM-D) Rating Scale. However, patients with higher C-reactive protein (CRP) levels, indicating low-grade inflammation, showed greater improvement in their depressive symptoms when taking minocycline.

Author Dr Valeria Mondelli, Clinical Reader in Psychoneuroimmunology at Institute of Psychiatry, Psychology & Neuroscience, King's College London, and Principal Investigator of the trial said: "Our findings are very exciting because we are showing that patients with increased levels of C reactive protein (an inflammatory biomarker) show a good response in terms of reduction of depressive symptoms following treatment with minocycline. Of the many patients with depression who do not respond to usual antidepressant treatment, we have shown in previous studies that in at least two thirds of patients this could be due to the increased levels of inflammation. Now, with this study, we are identifying a potential new effective treatment for these patients."

Predicting response
Patients underwent a blood sample to measure biological markers and a clinical assessment at the baseline visit and within 14 days the trial ending.

Researchers also found that levels of two biological markers, CRP and IL-6, can be used to predict minocycline response in depression. The study identified a specific threshold of CRP levels which is associated with the antidepressant effect of minocycline treatment. Another inflammatory marker, interferon-gamma, was reduced by the treatment with minocycline but not by placebo, suggesting specific pathways mediating the effects of minocycline on depressive symptoms.

Dr Mondelli added "We also identified the threshold of CRP levels that is associated with response to this anti-inflammatory treatment. This is very important as we may be able to identify with an easy blood test those patients who are going to benefit from treatment with an anti-inflammatory medication which is already used for other medical conditions and therefore easily available."

Dr Maria Antonietta Nettis, lead author and Clinical Research Associate at Institute of Psychiatry, Psychology & Neuroscience, King's College London said: "Integrating the measurement of biological markers such as CRP in patients' first assessments could help identifying potential responders to minocycline, which could be a relatively safe and well-tolerated addition to treatment in immune-related depression.

Although replications in larger samples are needed, we believe our study has a potentially important clinical impact, as we moved a step towards the identification of personalized treatments for Major depressive disorder (MDD)."

Credit: 
NIHR Maudsley Biomedical Research Centre

Researchers identify genetic dependencies in tumors that have undergone whole genome doubling

(Boston)--Researchers from Boston University School of Medicine (BUSM) have identified proteins that are essential for the viability of whole genome doubled tumor cells, yet non-essential to normal cells that comprise the majority of human tissue.

"Exploiting these vulnerabilities represents a highly significant and currently untapped opportunity for therapeutic intervention, particularly because whole genome doubling is a distinguishing characteristic of many tumor types," said corresponding author Neil J. Ganem, PhD, associate professor of pharmacology and medicine, section of hematology and medical oncology, at Boston University School of Medicine (BUSM).

The vast majority of human cells are diploid, meaning that they possess two copies of each chromosome (one from each parent). Numerous cell cycle controls exist to ensure that this state is maintained across successive cell divisions. Despite these controls, errors can occur that result in a whole genome doubling (WGD), in which a diploid cell transitions to a tetraploid state (where cells have four copies of each chromosome, instead of two). WGD cells are oncogenic, and their contribution to tumor development is quite significant: Computational analyses from the Ganem lab have revealed that approximately 35 percent of all solid tumors arise from cells that have experienced a WGD event.

While WGD confers traits that favor tumor formation, it also imposes numerous physiological stresses upon cells. This led Ganem and his colleagues to hypothesize that WGD tumor cells must acquire specific genetic alterations that enable them to tolerate the numerous defects imparted by a doubled cellular and genomic content, and that these tumor cells may therefore possess specific dependencies not present in normal diploid cells.

Using sequencing data from approximately 10,000 primary human cancer samples and data from nearly 600 cancer cell lines, the researchers found that WGD gives rise to common genetic traits that are accompanied by unique vulnerabilities. They identified several genes that are specifically required for the viability of WGD cells, including KIF18A, which is non-essential in normal diploid cells but becomes completely essential in WGD cancer cells.

"Currently, WGD status of cancer patients is not reported clinically because it does not inform treatment options. However, our study suggests that WGD cancer cells, based on their unique cellular physiology, may be specifically sensitive to a whole new variety of therapeutics. These findings may therefore validate the inclusion of WGD status as a new variable in future personalized medicine options," explained Ryan Quinton, an MD/PhD student in Ganem's lab who was the lead author on the study.

These findings appear online in Nature.

Credit: 
Boston University School of Medicine

New benchmark set to deliver optimal osteoporosis care throughout Asia Pacific

image: The first pan-Asia Pacific clinical practice standards for the screening, diagnosis and management of osteoporosis, targeting a broad range of high-risk groups

Image: 
The Asia Pacific Consortium on Osteoporosis (APCO)

The Asia Pacific Consortium on Osteoporosis (APCO) has today launched the first pan-Asia Pacific clinical practice standards for the screening, diagnosis, and management of osteoporosis, targeting a broad range of high-risk groups.

Published in Osteoporosis International today, 'The APCO Framework' comprises 16 minimum clinical standards set to serve as a benchmark for the provision of optimal osteoporosis care in the region.

Developed by APCO members representing key osteoporosis stakeholders, and multiple medical and surgical specialities, this set of clear, concise, relevant and pragmatic clinical standards aims to support national societies, guidelines development authorities, and health care policy makers with the development of new guidelines, and to encourage the revision of existing guidelines.

According to the Framework lead author, APCO Chairperson, and Director of the Osteoporosis and Bone Metabolism Unit at Singapore General Hospital, Dr Manju Chandran, Singapore, APCO employed a 5IQ analysis and the well-established Delphi Consensus process to analyse the 18 clinical practice guidelines currently available in the Asia Pacific region, to inform the development of The APCO Framework.

"Utilising a comprehensive, four-round Delphi consensus method enabled our APCO members who work in vastly different health care systems, to reach a remarkable level of consensus on a benchmark set of clinical standards for the provision of quality osteoporosis care for the Asia Pacific region."

The APCO Framework offers clinicians structured, well-articulated, and readily accessible clinical practice guidelines that define:

Individuals to be identified for assessment;

Investigations required;

Relevant indications for treatment;

Appropriate selection of interventions to be made;

The guidance and information patients need for self-care;

Integration of healthcare systems for optimal provision of care; and

The need, and methods for monitoring and improving the quality of osteoporosis care.

"Implementation of The APCO Framework, or a similar set of standards of care informed by the Framework, is expected to significantly reduce the burden of osteoporosis not only in the Asia Pacific region, but also worldwide. We hope that the Framework can serve as a stimulus for harmonisation of guidelines in other regions that have similar socio-economic diversity and heterogeneity of health care resources," Dr Chandran said.

Globally, the population aged 65 years or over increased from six per cent in 1990, to nine per cent in 2019.[1] This proportion is projected to rise to 16 per cent by 2050,1 meaning one in six people worldwide will be aged 65 years or over by 2050.[1] The number of people aged 60 years and over in the Asia-Pacific region - home to more than a third of the world's population aged 65 years and over, and to more elderly people than any other region [2] - is predicted to triple between 2010 and 2050, reaching a staggering 1.3 billion people.[3]

Osteoporotic fractures among Asia-Pacific populations are expected to increase exponentially, not only because of the region's rapidly aging population, but also due to mounting urbanisation, and the subsequent increase in sedentary lifestyles.[4]

Despite the presence of generally safe and effective treatments for osteoporosis, as many as five in six patients presenting to their primary care physician (PCP), or to a hospital with a fragility fracture, will not be assessed for osteoporosis, nor appropriately managed to prevent further fracture.[5]

According to Medical Director of Osteoporosis Australia, and APCO Executive Committee member, Professor Peter Ebeling AO, Australia, as many as half of those who have sustained a hip fracture, have already experienced a previous fracture at other skeletal sites.

"In fact, a prior fracture at any site is associated with a doubling of future fracture and mortality risk. The unfortunate ramifications of the gross under-diagnosis and under-treatment of osteoporosis is that a large number of people sustain further debilitating secondary fractures, which places a substantial, but importantly, preventable burden on already strained healthcare systems," said Prof Ebeling.

A fragility fracture, which occurs every three seconds worldwide, [6] compromises quality of life and loss of independence. [6,7] Concerningly, one-in-four patients who sustain a hip fracture die within a year, and less than half of those who survive, regain their previous level of function.[8,9] In 2010, an estimated 158 million people aged 50 years and above were at high risk for osteoporotic fracture - a figure which is set to double by 2040.[10]

According to International Osteoporosis Foundation (IOF) CEO and APCO Executive Committee member, Dr Philippe Halbout, Switzerland, these alarming statistics, coupled with the anticipated, exponential rise in osteoporotic fractures among Asia-Pacific populations, warrant a standardised set of minimum clinical standards for the region.

"Anecdotal evidence to date reveals significant inconsistencies in osteoporosis clinical practice guidelines in the Asia Pacific region, which vary widely in scope and recommendations. This was confirmed when we analysed the 18 guidelines."

"Implementation of the minimum clinical standards proposed by The APCO Framework, and reform of existing guidelines, will support clinical improvement initiatives, while also paving the way for a more holistic approach to osteoporosis care, and ultimately, greater consistency across all national and regional clinical practice guidelines in the region," Dr Halbout said.

Credit: 
International Osteoporosis Foundation